• BeiGene outlines growth plans as oncology pipeline expands AD HOC NEWS Wed, 08 Jul 2026 15:06:09 GMT
• BeiGene Ltd shares and business outlook amid global oncology expansion AD HOC NEWS Tue, 07 Jul 2026 15:32:31 GMT
• Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $416 Moomoo Tue, 07 Jul 2026 13:31:00 GMT
• The Tislelizumab Collaboration - Genmab builds a long-term cancer antibody franchise AD HOC NEWS Sun, 05 Jul 2026 14:05:56 GMT
• Brukinsa from BeiGene - BTK inhibitor pushes deeper into US lymphoma care AD HOC NEWS Sat, 04 Jul 2026 22:35:46 GMT
• BeiGene outlines its oncology growth strategy as global partnerships expand AD HOC NEWS Sat, 04 Jul 2026 18:32:02 GMT
• BeiGene Ltd highlights global oncology strategy as research pipeline expands AD HOC NEWS Fri, 03 Jul 2026 17:39:51 GMT
• BeiGene stock and the oncology pipeline. How the biotech positions for long-term growth AD HOC NEWS Fri, 03 Jul 2026 11:09:32 GMT
• Morning Market Update | BeiGene Surges More Than 4% as the Phase 3 Clinical Trial of Brukinsa Yields Positive Results. 富途牛牛 Fri, 03 Jul 2026 02:03:24 GMT
• wolfe research maintains beigene(onc.us) with buy rating, maintains target price $340 Moomoo Thu, 02 Jul 2026 13:06:37 GMT
• major bank ratings | ubs: slightly lowers beigene’s target price to $456, reiterates “buy” rating Bitget Thu, 02 Jul 2026 07:20:59 GMT
• beigene brukinsa capsules from beigene - targeted btk inhibitor gains ground in us lymphoma care AD HOC NEWS Wed, 01 Jul 2026 22:16:26 GMT
• biopharmaceutical company beigene is required to pay 446 million yuan in back taxes. ChemNet Mon, 29 Jun 2026 04:07:06 GMT
• Tislelizumab from BeiGene Ltd - PD-1 antibody pushes into frontline cancer care AD HOC NEWS Sun, 28 Jun 2026 02:37:00 GMT
• beone medicines (onc) deepens cancer ties with blood cancer united and new hematology data: what changes? Sahm Fri, 26 Jun 2026 12:32:19 GMT
• beone boosts support for blood cancer united with $5m commitment Fierce Pharma Fri, 26 Jun 2026 07:57:07 GMT
• morning market update | beigene surges more than 3%, turning profitable in q1 and raising its full-year guidance. 富途牛牛 Tue, 23 Jun 2026 02:02:52 GMT
• beigene ltd (onc) technical analysis: support, resistance, indicators & moving averages TradingKey Mon, 22 Jun 2026 07:00:00 GMT
• morning market update | beigene plunges nearly 4%, with multiple factors weighing on its stock price. 富途牛牛 Mon, 22 Jun 2026 02:03:08 GMT
• morning market update | beigene surges more than 4%, posts first-quarter profit and raises its guidance. 富途牛牛 Sun, 21 Jun 2026 02:02:05 GMT
• targeted hope for lymphoma patients - beigene’s brukinsa leans into everyday use Ad-hoc-news.de Fri, 19 Jun 2026 02:16:41 GMT
• intraday highlights | beigene surges more than 4%, raising its full-year revenue guidance. 富途牛牛 Fri, 19 Jun 2026 02:01:58 GMT
• beigene ltd (onc) risk assessment: volatility, financial risk & investment risk TradingKey Wed, 17 Jun 2026 21:23:22 GMT
• beigene ltd (onc) financial health: profitability & balance sheet analysis TradingKey Wed, 17 Jun 2026 21:18:57 GMT
• beigene ltd (onc) technical analysis: support, resistance, indicators & moving averages TradingKey Wed, 17 Jun 2026 21:18:57 GMT
• beigene ltd (onc) earnings forecast: future eps & revenue growth estimates TradingKey Wed, 17 Jun 2026 21:07:44 GMT
• beigene ltd (onc) valuation: pe, pb & fair value analysis TradingKey Wed, 17 Jun 2026 20:55:47 GMT
• beigene stock - wednesday operations and strategy update AD HOC NEWS Wed, 17 Jun 2026 17:17:32 GMT
• beigene ltd (onc) revenue breakdown: business segments, regional revenue & profit contribution TradingKey Wed, 17 Jun 2026 09:21:22 GMT
• Beigene Ltd (ONC) Dividends & Stock Splits: Historical Payouts and Event Timeline TradingKey Wed, 17 Jun 2026 07:46:44 GMT
• Will New BTK‑Resistant CLL Data and Fast Track Status Reshape BeOne Medicines' (ONC) Narrative Sahm Wed, 17 Jun 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): quarterly earnings and r&d push keep biotech in focus AD HOC NEWS Tue, 16 Jun 2026 07:00:00 GMT
• beigene ltd (onc) earnings forecast: future eps & revenue growth estimates TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• beigene ltd (onc) valuation: pe, pb & fair value analysis TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• beigene ltd (onc) technical analysis: support, resistance, indicators & moving averages TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• guggenheim maintains beigene(onc.us) with buy rating, maintains target price $420 Moomoo Mon, 15 Jun 2026 11:33:00 GMT
• baker bros 13d/a shows 8% onc stake and new beigene (onc) lead director Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): analyst updates put china-focused biotech back in focus Ad-hoc-news.de Fri, 12 Jun 2026 07:00:00 GMT
• here's how much you would have made owning beone medicines stock in the last 10 years Sahm Thu, 11 Jun 2026 07:00:00 GMT
• morning market update | beigene plunges more than 3%, with short interest surging over sixfold in a single day. 富途牛牛 Thu, 11 Jun 2026 02:02:53 GMT
• beigene ltd stock: why the biotech name remains on us investors' radar AD HOC NEWS Tue, 09 Jun 2026 07:00:00 GMT
• a look at beone medicines (onc) valuation after analyst upgrades and positive asco 2026 clinical updates Sahm Mon, 08 Jun 2026 16:36:31 GMT
• beigene ltd stock (us07725l1026): cancer drug specialist in focus after latest clinical and regulato Ad-hoc-news.de Mon, 08 Jun 2026 07:00:00 GMT
• earnings call transcript: beone medicines q1 2026 shows strong growth Investing.com Sat, 06 Jun 2026 02:16:30 GMT
• is beone medicines (onc) quietly recasting its hematology roots into a multi-franchise oncology platform? Sahm Fri, 05 Jun 2026 18:39:33 GMT
• wolfe research maintains beigene(onc.us) with buy rating, maintains target price $340 Moomoo Fri, 05 Jun 2026 07:00:00 GMT
• barclays maintains beigene(onc.us) with buy rating, maintains target price $409 Moomoo Thu, 04 Jun 2026 10:31:00 GMT
• hong kong stock ratings summary: cicc maintains beigene with an outperform rating. 富途牛牛 Thu, 04 Jun 2026 07:00:00 GMT
• guggenheim maintains beigene(onc.us) with buy rating, maintains target price $420 富途牛牛 Wed, 03 Jun 2026 19:55:44 GMT
• wolfe research maintains beigene(onc.us) with buy rating, maintains target price $340 富途牛牛 Wed, 03 Jun 2026 19:55:20 GMT
• a quick look at today's ratings for beigene(onc.us), with a forecast between $340 to $436 Moomoo Wed, 03 Jun 2026 07:00:00 GMT
• beone medicines asco data highlights oncology pipeline and revenue upside potential Sahm Wed, 03 Jun 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): shares firmer after hong kong price move and recent q1 2026 update AD HOC NEWS Tue, 02 Jun 2026 01:13:41 GMT
• Ireland reimburses BeOne’s Brukinsa for relapsed marginal zone lymphoma The Pharma Letter Mon, 01 Jun 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): shares ease after recent slide as investors eye valuation metrics AD HOC NEWS Fri, 29 May 2026 07:00:00 GMT
• beone medicines: recent fda approval rewrites one-drug narrative Sahm Fri, 22 May 2026 10:16:21 GMT
• beigene (06160.hk) received an increase of 943,200 h-shares from capital group of the united states, valued at approximately usd 2... 富途牛牛 Fri, 22 May 2026 10:07:05 GMT
• jefferies maintains beigene(onc.us) with hold rating, raises target price to $333 Moomoo Thu, 21 May 2026 17:09:29 GMT
• beigene ltd stock (us07725l1026): brukinsa tops $2.5 billion annual run-rate as us oncology footprin AD HOC NEWS Thu, 21 May 2026 09:25:20 GMT
• BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative Sahm Thu, 21 May 2026 07:00:00 GMT
• beone medicines wins fda nod for beqalzi in mantle cell lymphoma Sahm Thu, 21 May 2026 07:00:00 GMT
• then there were two: beone moves beyond single-blockbuster dependence thebambooworks.com Thu, 21 May 2026 06:35:50 GMT
• jpmorgan resumed coverage of beigene with an overweight rating and a price target of usd 415. Moomoo Wed, 20 May 2026 11:35:20 GMT
• BeOne kicks off ‘One Save Changes Everything’ campaign with Tim Howard Fierce Pharma Wed, 20 May 2026 07:00:00 GMT
• hong kong stock market update | beigene (06160.hk) rises nearly 3% after sotorasib receives u.s. fda approval; company's q1 net pr... 富途牛牛 Wed, 20 May 2026 06:35:36 GMT
• jpmorgan resumed coverage of beigene with an overweight rating and a price target of usd 415. Moomoo Tue, 19 May 2026 07:00:00 GMT
• abbvie’s trade secret suit against a chinese rival gets green light Life Sciences Intellectual Property Review Mon, 18 May 2026 07:00:00 GMT
• beigene stock (us0937121079): oncology specialist in focus after latest quarterly figures AD HOC NEWS Sun, 17 May 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): cancer drug approvals and earnings keep spotlight on biotech AD HOC NEWS Sun, 17 May 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): cancer drug specialist in focus after latest trial and r&d updates AD HOC NEWS Sat, 16 May 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): oncology biotech in focus after recent earnings and pipeline updat AD HOC NEWS Sat, 16 May 2026 07:00:00 GMT
• beigene stock (us0937121079): oncology player in focus after recent earnings and pipeline updates AD HOC NEWS Sat, 16 May 2026 07:00:00 GMT
• beone medicines wins conditional fda nod for cancer drug in rare blood cancer Sahm Fri, 15 May 2026 09:08:30 GMT
• John Oyler: Rewiring Operations in Oncology Pharmaceutical Executive Fri, 15 May 2026 07:00:00 GMT
• beigene stock (us07725l1026): beqalzi receives us fda accelerated approval AD HOC NEWS Thu, 14 May 2026 07:58:53 GMT
• beigene stock (us0937121079): recent clinical trial updates drive investor interest AD HOC NEWS Thu, 14 May 2026 07:00:00 GMT
• earnings preview: beigene to report financial results pre-market on may 06 Moomoo Wed, 13 May 2026 13:17:47 GMT
• beigene (06160.hk) will release its financial report on may 6. Moomoo Wed, 13 May 2026 08:45:00 GMT
• BeiGene Can’t Toss AbbVie Trade Secrets Suit Over Cancer Therapy Bloomberg Law News Wed, 13 May 2026 07:00:00 GMT
• earnings preview: beigene to report financial results pre-market on may 12 Moomoo Tue, 12 May 2026 05:42:14 GMT
• beigene (06160.hk) will release its financial report on may 12. Moomoo Tue, 12 May 2026 05:42:14 GMT
• beone medicines (onc) is up 7.4% after guidance hike and priority review win in her2 cancer Sahm Mon, 11 May 2026 07:00:00 GMT
• beone medicines recognized as 'outstanding global oncology company of the year' at hkct business awards 2026 finanzen.at Mon, 11 May 2026 03:30:12 GMT
• citi raised its target price for beigene (onc.us) to $453 following a strong first-quarter performance. 富途牛牛 Mon, 11 May 2026 02:11:39 GMT
• major bank ratings | citi: beigene reports strong q1 results, target price raised to $453 Bitget Sun, 10 May 2026 07:00:00 GMT
• BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology S-GE Sat, 09 May 2026 20:30:09 GMT
• hong kong stock announcements highlights | beigene's q1 revenue increased by over 30% year-on-year; muyuan foods' april sales reac... 富途牛牛 Sat, 09 May 2026 11:10:39 GMT
• a quick look at today's ratings for beigene(onc.us), with a forecast between $395 to $424 Moomoo Fri, 08 May 2026 13:00:00 GMT
• beigene (688235): full-year revenue and profit guidance raised; major asco data due to be released 富途牛牛 Fri, 08 May 2026 11:12:00 GMT
• results: beone medicines ag beat earnings expectations and analysts now have new forecasts Sahm Fri, 08 May 2026 07:00:00 GMT
• BeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial Fierce Biotech Thu, 07 May 2026 07:00:00 GMT
• beone shelves 5 cancer programs, halts ph. 2 arthritis trial Fierce Biotech Thu, 07 May 2026 07:00:00 GMT
• beone medicines (onc) eps surge tests bullish profitability narratives Sahm Thu, 07 May 2026 07:00:00 GMT
• beigene turned profitable in q1, with over 70% of its revenue coming from a single blockbuster product, while growth significantly... Moomoo Thu, 07 May 2026 05:23:26 GMT
• major bank ratings | morgan stanley: beigene's first quarter earnings exceed expectations, u.s. stock target price raised to $395 Bitget Thu, 07 May 2026 04:13:02 GMT
• ubs group raised its target price for beigene (onc.us) to $465 following strong first-quarter results. 富途牛牛 Thu, 07 May 2026 03:49:43 GMT
• morgan stanley raises beigene (onc.us) target price to $395, citing stronger-than-expected q1 results. 富途牛牛 Thu, 07 May 2026 03:06:25 GMT
• goldman sachs has raised its target price for beigene (onc.us) to $414.46, maintaining a 'buy' rating. 富途牛牛 Thu, 07 May 2026 02:47:47 GMT
• beigene reported a 31% year-over-year increase in q1 revenue, achieving a net profit of 1.608 billion yuan and reversing previous ... 富途牛牛 Thu, 07 May 2026 01:58:11 GMT
• hong kong stock movement | beigene (06160) opened more than 4% higher post-earnings; q1 net profit increased by 178.02 times year-... 富途牛牛 Thu, 07 May 2026 01:25:50 GMT
• star market daily: beigene projects revenue of up to 45.2 billion yuan by 2026; national integrated circuit fund reduces stake in ... 富途牛牛 Wed, 06 May 2026 13:18:31 GMT
• major bank ratings | morgan stanley: beigene's first quarter earnings exceed expectations, u.s. stock target price raised to $395 Bitget Wed, 06 May 2026 12:43:40 GMT
• esophageal cancer treatment market is expected to hit us$ 2.66 openPR.com Wed, 06 May 2026 10:57:43 GMT
• BeiGene's Q1 revenue increased by 31% year-on-year, with a net profit of 1.608 billion yuan achieving a turnaround | Earnings Repo... Moomoo Wed, 06 May 2026 07:00:00 GMT
• BeiGene turned profitable in Q1, with over 70% of its revenue coming from a single blockbuster product, while growth significantly... Moomoo Wed, 06 May 2026 07:00:00 GMT
• Earnings call transcript: BeOne Medicines Q1 2026 shows strong growth Investing.com Wed, 06 May 2026 07:00:00 GMT
• hong kong stock announcements highlights | beigene's q1 revenue increased by over 30% year-on-year; muyuan foods' april sales reac... 富途牛牛 Wed, 06 May 2026 07:00:00 GMT
• beone chooses degradation over inhibition | apexonco - clinical trials news and analysis Oncology Pipeline Wed, 06 May 2026 07:00:00 GMT
• beigene reported a 31% year-over-year increase in q1 revenue, achieving a net profit of 1.608 billion yuan and reversing previous ... 富途牛牛 Wed, 06 May 2026 07:00:00 GMT
• intelligent morning hk stock insights | spot prices of lithium carbonate have risen significantly; beigene (06160) reported a 178.... Moomoo Wed, 06 May 2026 07:00:00 GMT
• beone eyes huahui health’s trispecific hh-160 with $2b option deal BioWorld News Tue, 05 May 2026 16:00:00 GMT
• china’s beone eyes global rights to huahui health’s pre-clinical cancer therapy Yicai Global Mon, 04 May 2026 13:08:07 GMT
• wells fargo initiates beigene(onc.us) with buy rating, announces target price $400 富途牛牛 Mon, 04 May 2026 09:50:34 GMT
• beone eyes huahui health’s trispecific hh-160 with $2b option deal BioWorld News Mon, 04 May 2026 07:00:00 GMT
• apac healthcare weekly (may 3) – simcere, beigene, otsuka, kyowa kirin, sun pharma Smartkarma Sun, 03 May 2026 02:12:37 GMT
• china’s beone eyes global rights to huahui health’s pre-clinical cancer therapy Yicai Global Sat, 02 May 2026 13:07:16 GMT
• earnings preview: beigene to report financial results pre-market on may 06 Moomoo Fri, 01 May 2026 01:00:36 GMT
• china’s beone eyes global rights to huahui health’s pre-clinical cancer therapy Yicai Global Thu, 30 Apr 2026 13:15:25 GMT
• Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal BioWorld News Thu, 30 Apr 2026 07:00:00 GMT
• BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui Fierce Biotech Thu, 30 Apr 2026 07:00:00 GMT
• beone obtains global rights to huahui health’s trispecifics for up to $1.53bn Citeline News & Insights Tue, 28 Apr 2026 08:23:25 GMT
• china’s beone eyes global rights to huahui health’s pre-clinical cancer therapy 一财全球Yicai Global Tue, 28 Apr 2026 07:48:40 GMT
• BeOne joins the VEGF competition, but with a trispecific antibody Endpoints News Tue, 28 Apr 2026 07:00:00 GMT
• bofas maintains buy on beigene (06160.hk) with tp at hkd243.83 AASTOCKS.com Tue, 28 Apr 2026 02:26:00 GMT
• bofas maintains buy on beigene (06160.hk) with tp at hkd243.83 AASTOCKS.com Mon, 27 Apr 2026 07:00:00 GMT
• early session movements | beigene‐b plummets over 3%, affected by multiple factors affecting stock price fluctuations 富途牛牛 Sat, 25 Apr 2026 02:03:22 GMT
• morning market movements | beigene falls over 3% as development of egfr degradant suspended 富途牛牛 Thu, 23 Apr 2026 07:00:00 GMT
• aacr 2026: moderna, revolution, zymeworks and beone showcase new data BioSpace Tue, 21 Apr 2026 07:00:00 GMT
• beigene ltd stock (us07725l1026): is its oncology pipeline strong enough to unlock new upside? AD HOC NEWS Sun, 19 Apr 2026 14:43:50 GMT
• beigene (06160.hk) 1q25 results: profit side reversed losses in line with expectations 富途牛牛 Fri, 17 Apr 2026 18:41:18 GMT
• [schedule 13d/a] beone medicines ltd. amended major shareholder report Stock Titan Thu, 16 Apr 2026 07:00:00 GMT
BeiGene, Ltd(NASDAQ:BGNE) 
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantl...
Website: http://www.beigene.com
Founded: 2010
Full Time Employees: 9,400 (Dec 2022)
Sector: Healthcare
Industry: Biotechnology